HIV/TB/STD

Pediatric ID

Adult ID

Global ID

Trainee

Symposium

301 - HPV Update

Co-organized with the Centers for Disease Control and Prevention

Learning Objectives:

At the conclusion of this session, participants will be able to:

• describe epidemiology of human papilloma virus infections
• recognize the science behind planning for global elimination of cervical cancer
• review the immunology of HPV vaccines

Presentations:

• 3:15 PM - 3:40 PM

  2864 - Questions in HPV Epidemiology-Latency, Reactivation and Risk in Older Ages
  Rachel L. Winer, PhD, MPH – University of Washington
• 3:40 PM - 4:05 PM

  2865 - Modelling HPV Natural History and Vaccine Impact-Informing Policy and Acceleration of Global Elimination of Cervical Cancer
  Marc Brisson, PhD – Université Laval
• 4:05 PM - 4:30 PM

  2866 - HPV Vaccine Mechanisms-Explaining the Basis for Unexpected Effectiveness of Current Formulations and Horizon for New Vaccines
  John T. Schiller, PhD – National Cancer Institute

Moderator(s)

• 

  Inger Damon, MD, PhD

  Director Division of High Consequence Pathogens and Pathology
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• LM

  Lauri Markowitz, MD

  Team Lead, Associate Director for Science
  Centers for Disease Control and Prevention
  Atlanta, GA

  Disclosure: Nothing to disclose
• 

  Elizabeth Unger, PhD, MD

  Chief Chronic Viral Diseases Branch
  Centers for Disease Control and Prevention
  Atlanta, GA

  Disclosure: Nothing to disclose

Speaker(s)

• 

  Marc Brisson, PhD

  Professor
  Université Laval
  Quebec, QC, Canada

  Disclosure: Nothing to disclose
• 

  John Schiller, PhD

  NIH Distinguished Investgator
  National Cancer Institute
  Bethesda, MD

  Disclosure: GlaxoSmithKline: Inventor on U.S. government-owned patent licensed to company
  Merck: Inventor on U.S. government-owned patent licensed to company
• 

  Rachel Winer, PhD, MPH

  Professor
  University of Washington
  Seattle, WA

  Disclosure: Nothing to disclose